TNFRSF11A and osteoporosis: Our recent findings have shown that GD patients with osteopenia and osteoporosis have elevated levels of bone biomarkers related to the activation of bone resorption and dysregulation of the RANKL-OPG-RANK and Wnt/β-catenin pathway (15–17).